Huiyu Pharmaceutical

What Huiyu Pharmaceutical does

Huiyu Pharmaceutical (四川汇宇制药股份有限公司, Shanghai STAR Market ticker 688553) is a Chinese pharmaceutical company founded in 2010 and headquartered in Neijiang, Sichuan, with manufacturing operations in Neijiang and a 1,500-person-capacity R&D base in Chengdu Tianfu International Bio-city. The company specializes in anti-tumor injectable drugs — including lyophilized injections, complex formulations, and liposomal products such as amphotericin B liposome — that hold EU GMP certification and have passed US FDA on-site inspection, with over 16 international GMP certifications accumulated. Its marketed portfolio exceeds 40 domestic-approved injectable products spanning oncology (e.g., methotrexate, oxaliplatin, irinotecan, carfilzomib, paclitaxel), anti-infectives (molidinidazole sodium chloride, polymyxin B), hepatobiliary drugs, iron supplements, and supportive care; internationally, products are commercialized through wholly-owned UK subsidiary SeaCross Pharma (海玥药业) plus authorized distributors across 60+ countries and 6 continents, with 300+ overseas market authorizations on file.

Huiyu operates a dual-track business model combining (a) high-barrier generic injectable manufacturing, with 10 products having won national volume-based procurement (集采) bids, selling to nearly 7,000 hospitals in China and 1,000+ hospitals across UK and EU markets; and (b) a CDMO one-stop-service platform spanning pharmaceutical intermediates, APIs, formulations, and international registration support for domestic and foreign pharma clients seeking market entry. Revenue is generated through one-time pharmaceutical product sales, API external sales, and contract development/manufacturing service fees, sold predominantly via the company's China Marketing Center direct sales force and authorized distributors abroad.

The company's innovation pipeline is anchored by 17 technical platforms and 80+ R&D projects, including 14 Class 1 innovative drugs and 5 modified new drugs. Between October 2023 and July 2025, Huiyu secured IND approvals for five pipeline assets: HY-0002a (dual KRASG12C/PI3K inhibitor), HY-0006 (SOS1 inhibitor, first globally), HY-0007 (PD-1/TIGIT/IL-15 tri-specific fusion protein), HY-0001 (CDCP1-targeted ADC), and HY-0005 (CD3/MSLN/PD-L1 tri-specific T-cell engager), alongside HY-2003 (modified new drug for submental fat) and HY-07121 subcutaneous formulation. The workforce of 251–500 employees is weighted heavily toward R&D (45%+), with 30+ doctoral researchers and 10+ national/provincial-level innovative talents, supporting R&D spend of 3.6 hundred million RMB in 2023 representing 38.48% of revenue. State-level designations include National Enterprise Technology Center (2023), National Technology Innovation Demonstration Enterprise (2023), National Postdoctoral Research Station (2024), and National Green Factory (2023).

Name

Huiyu Pharmaceutical

Legal name

四川汇宇制药股份有限公司

Website

https://huiyupharma.com

Company type

Public

Founded year

2010

Operating status

Operating

Headcount range

251–500 employees

Short description

Huiyu Pharmaceutical (Shanghai STAR Market ticker 688553) is a Neijiang, Sichuan-based pharmaceutical company that manufactures EU GMP-certified anti-tumor injectable drugs and APIs, sells through a wholly-owned UK subsidiary plus distributors to 7,000+ hospitals in China and 60+ countries globally, and develops Class 1 innovative biologics and small molecules across oncology, anti-infectives, and medical aesthetics.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals (Anti-tumor Injectable Drugs)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Oncology Specialty Pharmaceuticals (HLAIACAA)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Anti-tumor injectable drugs
• Oncology pharmaceutical manufacturing
• EU GMP certified injectables
• CDMO pharmaceutical services
• Innovative oncology biologics

Headquarters

HQ city

Neijiang

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical Product Sales - Domestic China: Sales of approved generic and innovative drugs to hospitals and medical institutions across China through direct sales force and bidding into national procurement programs.
2. Pharmaceutical Product Sales - International: Sales of anti-tumor injectable products in European markets through UK subsidiary and authorized distributors, covering over 60 countries globally.
3. CDMO Services: Contract development and manufacturing services for domestic and international pharmaceutical companies, covering full value chain from intermediates to APIs to formulations.
4. API External Sales: Active pharmaceutical ingredient sales to other pharmaceutical manufacturers.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels6 records

Core offering

Huiyu Pharmaceutical manufactures and commercializes anti-tumor injectable drugs and complex generic injectables from EU GMP certified facilities in Neijiang, China. The company sells its oncology products to over 7,000 Chinese hospitals and 1,000+ European hospitals through direct sales forces, while providing full-chain CDMO services from intermediates to finished formulations. Its innovation pipeline includes Class 1 biologic drugs (ADCs, tri-specific antibodies, bispecific fusion proteins) and small molecule inhibitors (KRASG12C, SOS1) in clinical development.

Product overview

Huiyu Pharmaceutical (汇宇制药) is a research-driven pharmaceutical company listed on the STAR Market (stock code: 688553), headquartered in Neijiang, Sichuan, with a research base in Chengdu Tianfu International Bio-city. The company specializes in anti-tumor injectable drugs holding EU GMP certification and has developed a comprehensive portfolio spanning generic drugs, innovative biologics, small molecule innovation drugs, and CDMO manufacturing services. The marketed product portfolio includes over 40 injectable formulations covering anti-tumor agents (如注射用卡非佐米/汇芙定, 注射用盐酸美法仑/汇芙安, 注射用塞替派/汇立泰, 克拉屈滨注射液/汇必定, 注射用氨磷汀/汇泰吉), supportive care drugs, anti-infectives, iron supplements (羧基麦芽糖铁注射液, 蔗糖铁注射液), hepatobiliary drugs (乙酰半胱氨酸注射液/宇可安), and anesthetics/muscle relaxants (苯磺顺阿曲泬铵). The innovation pipeline includes 6+ Class 1 innovative drugs in clinical stages: ADC创新药HY-0001, 双靶点小分子HY-0002a, 三特异性抗体HY-0005, SOS1抑制剂HY-0006, and 三靶点抗体融合蛋白HY-0007, alongside improved new drug HY-2003. The company also operates a global CDMO one-stop service platform covering the entire pharmaceutical value chain from intermediates to finished products including complex formulations. International operations span over 60 countries with 300+ overseas market approvals.

Differentiator

Problem solved

Functional benefit

Products and services

• Carfilzomib for Injection (注射用卡非佐米 / 汇珉定) Carfilzomib for Injection is a next-generation proteasome inhibitor anti-tumor drug approved by NMPA for use in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy including a proteasome inhibitor and an immunomodulatory drug. Available in 10mg, 30mg, and 60mg specifications. Listed as National Medical Insurance Category B drug, dual-channel managed.
• Amphotericin B Liposome for Injection (注射用两性霉素B脂质体) Liposomal formulation of amphotericin B for injection, chemical drug class 4. Indicated for the treatment of systemic fungal infections including cryptococcosis, blastomycosis, disseminated candidiasis, coccidioidomycosis, aspergillosis, histoplasmosis, mucormycosis, and visceral leishmaniasis. Currently in registration stage with NMPA.
• Molidinidazole Sodium Chloride Injection (吗啉硝唑氯化钠注射液) Third-generation nitroimidazole class antibacterial injection approved by NMPA. Used for treating sensitive bacterial infections in adults including pelvic inflammation and appendicitis. National medical insurance category B. Huiyu was the first company to receive approval for this generic drug, deemed equivalent to passing consistency evaluation.
• Amifostine for Injection (注射用氨磷汀) Amifostine for Injection 0.5g specification is a cytoprotective agent (anti-tumor adjuvant) chemical drug class 3, used to reduce nephrotoxicity from cisplatin and the toxic effects of radiation therapy on normal oral cavity tissues during cancer treatment. Category B national medical insurance drug. Produced by subsidiary Huiyu Haiyue.
• Methocarbamol Injection (美索巴莫注射液) Methocarbamol Injection is a CNS inhibitor with sedative and skeletal muscle relaxant effects for the treatment of acute musculoskeletal pain. Specification 10ml:1g, chemical drug class 3, approved by NMPA. Produced by subsidiary Huiyu Haiyue.
• Methotrexate Injection 1ml:25mg (甲氨蝶呤注射液) Methotrexate Injection 1ml:25mg is a chemical drug class 4 anti-metabolite antineoplastic drug with pre-filled syringe format. Has broad-spectrum anti-tumor activity used for breast cancer, gestational choriocarcinoma, osteosarcoma, leukemia, and psoriasis chemotherapy. This is the second specification of Huiyu's methotrexate injection to pass consistency evaluation.
• Polymyxin B Sulfate for Injection (注射用硫酸多黏菌素B) Polymyxin B Sulfate for Injection is a polypeptide class antibiotic approved by NMPA. Used for the treatment of severe infections caused by carbapenem-resistant gram-negative bacteria in adult patients, including meningitis and bacteremia caused by Pseudomonas aeruginosa. Specification 500,000 units.
• HY-0002a (HYP-2090PTSA Capsule) - KRASG12C/PI3K Dual-Target Small Molecule Innovator Drug HY-0002a is a Class 1 chemical innovator drug that simultaneously inhibits KRASG12C and PI3K, providing dual-pathway blockade for the treatment of KRASG12C-mutated advanced solid tumors including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Currently in clinical trial stage.
• HY-0001 (HY0001a) - CDCP1-targeted ADC Innovator Drug HY-0001 (HY0001a) is a Class 1 innovative therapeutic biologic antibody-drug conjugate (ADC) targeting CDCP1, which is highly expressed in gastric cancer, breast cancer, lung cancer, colorectal cancer, and pancreatic cancer, while normal tissues do not express or only low expression. IND approval received for treatment of advanced solid tumors.
• HY-0005 (HY05350) - CD3/MSLN/PD-L1 Tri-specific Antibody TCE Innovator Drug HY-0005 (HY05350) is a Class 1 innovative therapeutic biologic tri-specific antibody T-cell engager (TCE) targeting CD3, MSLN, and PD-L1. Recruits T cells through CD3, targets tumor cells through MSLN and PD-L1, and simultaneously relieves immunosuppression through PD-L1. IND approval received from NMPA for treatment of advanced solid tumors.
• HY-0007 (HY07121) - PD-1/TIGIT/IL-15 Bispecific Antibody Fusion Protein HY-0007 (HY07121) for Injection is a Class 1 innovative therapeutic biologic, a tri-target (PD-1/TIGIT/IL-15) bispecific antibody fusion protein for the treatment of advanced solid tumors. Enhances immune therapy efficacy and overcomes immune resistance by supplementing immune cell source and restoring exhausted immune cell function. First self-developed biological innovator drug to receive clinical trial approval from NMPA.
• HY-0006 (HYP-6589 Tablet) - SOS1 Small Molecule Inhibitor Innovator Drug HY-0006 (HYP-6589) is a high-selectivity SOS1 small molecule inhibitor (Class 1 chemical innovator drug) that specifically binds to the SOS1 catalytic region to block the formation of activated RAS-GTP state, inhibiting two critical signaling pathways of RAS-RAF-MAPK and RAS-PI3K-AKT-mTOR. IND application accepted for combined treatment with osimertinib for late-stage non-small cell lung cancer.
• HY-2003 Improved New Drug (Deoxycholic Acid New Formulation) HY-2003 is a Class 2.2 chemical drug improved new drug containing deoxycholic acid in a new formulation. Indicated for the improvement of moderate to severe submental fat accumulation (double chin) in adults. The new formulation aims to reduce injection site adverse reactions.
• CDMO International One-Stop Service Platform (CDMO国际一站式服务平台) Full pharmaceutical value chain CDMO (Contract Development and Manufacturing Organization) service covering pharmaceutical intermediates, APIs, and finished formulations. Services include drug small-pilot research and development, pilot scale-up, process validation, commercial production, domestic and international drug registration, and international drug sales cooperation covering six continents. Formulation types cover aseptic small-capacity injections and liposomes, microspheres, nanoparticles, and other high-end complex formulations.
• Oncology Marketed Injectable Product Portfolio (40+ marketed products) Comprehensive portfolio of over 40 marketed injectable products in the Chinese domestic market including oncology agents (Pemetrexed for Injection, Carboplatin Injection, Irinotecan Hydrochloride Injection, Oxaliplatin Injection, Paclitaxel injection, Gemcitabine Hydrochloride for Injection, etc.), anti-tumor supportive care drugs (Amifostine for Injection), anti-infectives, iron supplements (Ferric Carboxymaltose Injection, Iron Sucrose Injection), hepatobiliary drugs (Magnesium Isoglycyrrhizinate Injection), and muscle relaxants/anesthetics (Cisatracurium Besylate Injection). Many products have obtained marketing authorizations in 7 European countries (UK, France, Germany, Italy, Spain, Portugal, Northern Ireland).

Quantifiable outcome

• Products sold in over 60 countries with 300+ overseas approval documents
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered exploratory and core.

• Korea Trade-Investment Promotion Agency (KOTRA) Chengdu OfficeexploratoryGTM or Marketing PartnerKOTRA Chengdu Office and Korean Consulate General in Chengdu visited Huiyu to explore potential collaboration between Korean innovative pharma companies and Chinese pharma enterprises. The visit aims to establish a platform for bilateral exchanges in the pharmaceutical industry and promote trade cooperation.
• Japan External Trade Organization (JETRO) ChengduexploratoryGTM or Marketing PartnerJETRO Chengdu led by Chief Representative Takamitsu Akiha visited Huiyu to explore potential collaboration with Japanese pharmaceutical companies in API and injectable development and manufacturing. Huiyu expressed interest in deepening exchanges with Japanese pharma enterprises with JETRO's support.
• 内江市第二人民医院 (Neijiang Second People's Hospital)coreStrategic or Co-development PartnerHuiyu signed a joint postdoc training cooperation agreement with Neijiang Second People's Hospital on November 4, 2024. The partnership aims to integrate industry, academia, and research through deep collaboration to promote medical research innovation and translate scientific achievements into clinical applications.

Scale indicators19 records

Recent moves9 records

Expansion highlights6 records

Emerging players

• Innovent Biologics: Chinese biotech pioneer with approved PD-1 inhibitor (sintilimab) and multiple bispecific antibodies in development; directly competes with Huiyu's PD-1/TIGIT/IL-15 bispecific in oncology innovation space and reflects the biologics capability bar Huiyu is trying to clear.
• CStone Pharmaceuticals: Chinese oncology-focused biotech with multiple targeted therapies in development including KRAS-targeted agents; emerging player in similar innovative oncology niches to Huiyu's KRASG12C (HY-0002a) and SOS1 (HY-0006) targeting strategy.
• Akeso Biopharma: Chinese biotech focused on bispecific and multi-specific antibody development including PD-1/VEGF (ivonescimab) and PD-1/CTLA-4 bispecifics; overlapping target profile with Huiyu's HY-0007 PD-1/TIGIT/IL-15 tri-specific and a direct emerging competitor in next-gen immuno-oncology biologics.

Direct peers

• CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharma with strong oncology injectable and innovative drug portfolio, including complex injectables and CDMO capabilities; pursues the same branded product + CDMO + internationalization strategy as Huiyu in overlapping oncology and supportive care areas.
• Sino Biopharmaceutical: Hong Kong-listed Chinese pharma with diversified oncology, hepatology, and respiratory portfolio operating a branded generics + innovation hybrid model with international expansion focus; structurally similar to Huiyu in business model and target therapeutic areas.
• Luye Pharma Group: Chinese specialty pharma with oncology focus, complex injectable technology (liposomal formulations), and international operations including US/EU markets; closely comparable through oncology injectable core + international commercialization focus.
• Jiangsu Hengrui Medicine: Largest Chinese pharmaceutical company with broad oncology and specialty pharma portfolio spanning innovative drugs, biosimilars, and complex injectables; serves as benchmark for Chinese pharma innovation pipeline scale, branded generic + innovation hybrid model, and international expansion strategy that Huiyu is pursuing.

Others

• WuXi Biologics: Global leading biologics CDMO with extensive China + international footprint; directly relevant to Huiyu's biologics CDMO ambitions and Shanghai-listed platform; potential partner or competitor for biologics contract manufacturing adjacent to Huiyu's innovation pipeline.
• Pharmaron: China-headquartered global CRO/CDMO with API, formulation, and biologics services; shares Huiyu's CDMO business model on the small-molecule and complex formulation side, particularly comparable to Huiyu's full-value-chain CDMO positioning covering intermediates to finished injectable products.

Broad incumbents

• BeiGene: Chinese oncology-focused biotech with multiple approved innovative drugs (zanubrutinib, tislelizumab, pamiparib) and global commercial infrastructure including US/EU field forces; much larger scale than Huiyu but represents the strategic direction Huiyu is pursuing via innovation and global registration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Huiyu Pharmaceutical